Abstract
Background: Recent advancements in cancer treatment have shown the potential of PD-1/PD-L1 inhibitor (ICB) plus Viscum album L. (VA) therapy in improving survival rates for patients with advanced or metastasized non-small cell lung cancer (NSCLC). The objective of this study was to investigate factors associated with improved survival in NSCLC patients treated with a combination of ICB and VA. Methods: Patients with advanced or metastasized NSCLC from the accredited national Network Oncology registry were included in the real-world data study adhering to ESMO-GROW criteria. The study was conducted with ethics approval. Survival and the impact on hazard were compared between patients receiving PD-1/PD-L1 inhibitor therapy alone versus combinational PD-1/PD-L1 inhibitors and abnobaViscum therapy. Adjusted multivariate Cox proportional hazard analysis was utilized to examine factors linked to survival. Results: Enrolled patients (n = 300) had stage III or stage IV NSCLC, had a 1.19 male/female ratio and were 68 years old (median). Two hundred and twenty-two patients (74%) were in the control (CTRL, PD-1/PD-L1 inhibitor therapy) and seventy-eight patients (26%) in the combinational (COMB, PD-1/PD-L1 inhibitor plus abnobaViscum therapy) group. The three-year survival was significantly prolonged by 7 months when abnobaViscum therapy was added to the anti-PD-1/PD-L1 therapy (Comb: 13.8 months vs. Control: 6.8 months, p = 0.005). The three-year survival rate was 16.5% in the COMB group and two times higher than the three-year survival rate in the CTRL group (8.0%). Adjusted multivariable Cox regression analysis was performed for patients with PD-L1 positive (</=1%) NSCLC treated with a first-line PD-1 inhibitor and revealed that the addi-tion of abnobaViscum therapy to anti-PD-1 significantly lowered the hazard of death by 75% in (aHR: 0.25; 95%CI: 0.11-0.60, p=0.002). Conclusions: Our results indicate that addition of ab-nobaViscum therapy is significantly linked to enhanced survival in patients with advanced or metastasized NSCLC who are undergoing treatment with standard PD-1/PD-L1 inhibitor therapy irrespective of their age, tumor stage, ECOG status, surgery or radiation. The mechanisms could involve a synergistic modulation of the immune response, reduced primary PD-1/PD-L1 inhibitor resistance via immunogenic cell death and/or modification of the tumor microenvironment by combinational PD-1/PD-L1 inhibitor and abnobaViscum therapy. Our findings should be com-plemented with analyses of RCT or R-RCT. Trial registration: The study was registered retrospectively (DRKS00013335).
Competing Interest Statement
FS reports receiving grants from ABNOBA GmbH, Helixor Heilmittel GmbH, and Astrazeneca GmbH, outside the submitted work. RDH reports a consulting or advisory role with Amgen, Roche, Merck, Sanofi, Bayer, Ipsen, BMS, and MSD, as well as honoraria from Amgen, Astra-Zeneca, Bayer, BMS, Boehringer, Ipsen, Lilly, Medac, Merck, MSD, Roche, Saladax, and Sanofi, all outside the submitted work. RDH has also received research grants from Amgen, Medac, Merck, Roche, Saladax, and Sanofi, outside the submitted work. PG reports travel expenses from Ipsen Pharma and research grants from Helixor Heilmittel GmbH, outside the submitted work. HW reports honoraria from AstraZeneca and Berlin-Chemie, outside the submitted work. CG reports honoraria from AstraZeneca, Novartis, Chiesi, the German Society of Pneumology, Takeda, the German S3-Guideline on Complementary Medicine in the Treatment of Oncological Patients, and the Brandenburgian Cancer Society, all outside the submitted work. CG has also received grants from Wala AG and Iscador AG, outside the submitted work. CG is a member of the European Res-piratory Society, the German Society of Pneumology, Health Care Without Harm, the German Alliance for Climate Change and Health, and the Society of Anthroposophic Physicians. The remaining authors declare no competing interests.
Clinical Protocols
https://zenodo.org/records/13944797
Funding Statement
This study was funded by unrestricted research grants from ABNOBA GmbH Niefern-Oeschelbronn, Germany and Helixor GmbH Rosenfeld, Germany. By contract, researchers were independent from the funder.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Medical Association Berlin gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The word ,re-al - world was changed into to ,real world,.
Data Availability
All data produced in the present work are contained in the manuscript
